TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03338075

Intervention type: RADIATION
Intervention: fractionated stereotactic radiotherapy
Description: The regular prescription doses were 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.

Intervention type: RADIATION
Intervention: fractionated stereotactic radiotherapy
Description: The regular prescription doses were 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
Study: NCT03402503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast buccal film
Description: Film with active investigational product (montelukast) inserted and applied on inner cheek

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo buccal film
Description: Film with placebo (no active drug) inserted and applied on inner cheek
Study: NCT04985474

Intervention type: OTHER
Intervention: questionnaires
Study: NCT01378039

Intervention type: DRUG
Group type: OTHER
Intervention: comparison of treatment effect on different markers
Description: inhaled budesonide (400 µg BD) or placebo BD
Study: NCT01590485

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: starch
Description: 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saffron
Description: 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
Study: NCT04529863

Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab claim is used as the reference group.

Intervention type: DRUG
Intervention: Abatacept
Description: Abatacept claim is used as the exposure group.
Study: NCT05145270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram(No-specified) 10-20mg/d, once per day.
Study: NCT02683746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyophilized albiglutide DCC pen injector
Description: A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyophilized albiglutide DCC pen injector matching placebo
Description: A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide liquid auto-injector
Description: A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide liquid auto-injector matching placebo
Description: A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
Study: NCT01213576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole 400mg and ivermectin 200mcg/kg
Description: 400 mg orally given annually

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole 400mg and ivermectin 200mcg/kg
Description: 400 mg orally given annually

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole and ivermectin
Description: albendazole 800 mg and ivermectin 400mg orally given annually

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole 400mg and ivermectin 200mcg/kg
Description: Albendazole 400mg and ivermectin 200mcg/kg given twice a year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole 400mg and ivermectin 200mcg/kg
Description: Albendazole 400mg and ivermectin 200mcg/kg given twice a year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole 800mg and ivermectin 400mcg/kg bi-annually
Description: albendazole 800mg and ivermectin 400mcg/kg given twice a year
Study: NCT01811264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Participation Aid
Description: The PPA consists of a folder that addresses the three behaviors we hope to influence: agenda setting, asking questions, and making preferences known. The information inside contains sample questions for each section, with room for the patient to write her own questions. Each section models behavior by giving context for the items and specific example questions. It also addresses barriers to understanding by indicating that it is acceptable to ask questions when something is not clear or terms are unfamiliar.
Study: NCT02162407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human soluble insulin
Description: Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
Study: NCT04787523

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Patients have received neoadjuvant radiotherapy
Study: NCT04366999

Intervention type: PROCEDURE
Intervention: OAGB
Description: OAGB entails the creation of a long gastric tube by beginning 2 cm below the angular incisure starting from the lesser curvature side and then divided vertically upward by linear cutting staplers as calibrated with a 36 French bougie, followed by the creation of a single gastrojejunal anastomosis with an afferent biliopancreatic limb of 200 cm.
Study: NCT01591070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.1% tacrolimus once-weekly application for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.1% tacrolimus twice weekly application for 10 weeks
Study: NCT01097629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant High Dose (HD)
Description: Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants \<65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month Treatment (TRT) Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
Study: NCT01327222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg intravitreal bevacizumab
Study: NCT04254718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Storytelling
Description: Creation of a digital story about the infant with video and music selected by parents
Study: NCT02424097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste
Description: MI Paste \& MI Varnish- in-office:~varnish application once every 3 months; at baseline, at the end of month 3, 6, and 9 (4 applications)~- at-home: brushing with regular 1,100ppm F-toothpaste, 2x per day and MI Paste Plus, home application after brushing in the evening; 3-5 minutes with in-home application tray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1,100pm F-toothpaste and 0.5%NaF rinse
Description: Standard of care at-home:~Crest tooth brushing 2x per day - (recommendation OTC Fluoride-rinse in the evening at home 1x per day)
Study: NCT01097629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant Low Dose (LD)
Description: Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants \<65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
Study: NCT02088463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mobilization (manual therapy)
Description: mobilization is one of the manual therapy or treatments with the application of a gentle oscillatory passive movement to the spinal region specifically at the level of L3 in this study at the posterio-anterior direction.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mobilization
Description: placebo mobilization is a tactile stimulation at the same level L3 without application of any force.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound and infrared devices
Description: ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound and infrared devices
Description: ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems
Study: NCT00694057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE3286
Description: HE3286 10 mg per day (5 mg BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules BID
Study: NCT02663895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Description: Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated
Study: NCT02911688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gamma tocopherol
Description: The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after γT dosing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after placebo dosing.
Study: NCT03820245

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bixin
Description: Volunteers consumed bixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Norbixin
Description: Volunteers consumed norbixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lycopene
Description: Volunteers consumed lycopene capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers consumed placebo capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
Study: NCT02208245

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound: Axillary block
Description: Ultrasound guided axillary block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound: Infraclavicular block
Description: Ultrasound guided infraclvicular block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 20 ml of ropivacaine 0,5% in both groups ( axillary block and infraclavicular block)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 20 ml of ropivacaine 0,5% in both groups ( axillary block and infraclavicular block)
Study: NCT02274688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care Management
Description: Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.
Study: NCT00856310

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN475 (SAR164877)
Description: Subcutaneous administration REGN475 (SAR164877)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN475 (SAR164877)
Description: Subcutaneous administration REGN475 (SAR164877)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN475 (SAR164877)
Description: Subcutaneous administration REGN475 (SAR164877)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN475 (SAR164877)
Description: Subcutaneous administration REGN475 (SAR164877)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN475 (SAR164877)
Description: Subcutaneous administration REGN475 (SAR164877)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN475 (SAR164877)
Description: Subcutaneous administration REGN475 (SAR164877)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGN475 (SAR164877)
Description: Subcutaneous administration REGN475 (SAR164877)
Study: NCT01524991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 Days 1 \& 8 (all cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m2 Day 1 (all cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 10 mg/kg Day 1 (start cycle 3)
Study: NCT01956214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES Exercise
Description: receive FES while exercising

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mock FES Exercise
Description: participants will receive Mock FES
Study: NCT01498133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin-to skin contact
Description: Skin-to-skin contact consisted of placing the infant slightly worn (only diapers) in prone decubitus, upright against the mother's breast. The infant was restrained in position by a track that involved him with his/her mother. The mother sat in a chair positioned beside the infants' bed. A team member that accompanied the intervention monitored infants' temperature, heart rate and oxygen saturation.
Study: NCT03037281

Intervention type: DIAGNOSTIC_TEST
Intervention: Septic
Description: 30mls of blood will be sampled by venepuncture, or sampled from indwelling lines (in the case of septic patients on intensive care). Blood will be sampled using standard techniques, and transferred to EDTA containing blood bottles, and undergo processing immediately.

Intervention type: DIAGNOSTIC_TEST
Intervention: Septic
Description: 30mls of blood will be sampled by venepuncture, or sampled from indwelling lines (in the case of septic patients on intensive care). Blood will be sampled using standard techniques, and transferred to EDTA containing blood bottles, and undergo processing immediately.
Study: NCT04548557

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulin therapy
Description: It is passive immunization therapy. Plasma therapy is subjected to moderate to severe patients specially, while all effected individuals can take benefit of immunoglobulin therapy because dose of immunoglobulins can be controlled
Study: NCT02310009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (AN)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (AN)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise (EX)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise (EX)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control (CON)
Study: NCT00790309

Intervention type: PROCEDURE
Intervention: Weight loss surgery
Description: Weight loss surgery

Intervention type: PROCEDURE
Intervention: Laparoscopic abdominal surgeries
Description: laparoscopic abdominal surgeries
Study: NCT01439698

Intervention type: DEVICE
Intervention: Radio Frequency ablation Probe
Description: Any probe that can conduct radiofrequency ablation within biliary ducts.
Study: NCT04401020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442257
Description: Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion
Study: NCT03270956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Autologous selected renal cells (SRC)
Study: NCT02088463

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound and infrared devices
Description: ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems
Study: NCT02337218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SENSUS Pain Management System
Description: An electrical stimulation device worn on a band around the leg. This device was determined to be non-significant risk by the FDA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SENSUS Pain Management System
Description: An electrical stimulation device worn on a band around the leg. This device was determined to be non-significant risk by the FDA.
Study: NCT03671447

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICU Usual Care
Description: The control condition delivered at ICU is usual care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-ICU
Description: The experimental complex intervention ERIC consists of daily tele-medicine based rounds at ICU. Tele-ICU is implemented after a blended learning program for ICU staff which will be completed prior to the site's crossover.
Study: NCT00942318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detemir insulin, Aspart insulin, Metformin
Description: Insulin doses adapted by patients according to self monitoring blood glucose results.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir insulin, Aspart insulin, Metformin
Description: Insulin doses adapted by patients according to self monitoring blood glucose results.
Study: NCT02960568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: 30 mg oral primaquine one time
Study: NCT02042820

Intervention type: OTHER
Intervention: In vivo confocal microscopy (IVCM)
Description: IVCM is a sensitive tool for detecting dry eye-associated subclinical inflammation.

Intervention type: OTHER
Intervention: In vivo confocal microscopy (IVCM)
Description: IVCM is a sensitive tool for detecting dry eye-associated subclinical inflammation.
Study: NCT01606657

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation
Description: The patient will receive irrigation as a part of their wound care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Irrigation
Description: The patient will not receive irrigation as part of their wound care
Study: NCT04012489

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breath Stacking
Description: Patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air Stacking
Description: The same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
Study: NCT03138993

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient decision aid
Description: Web-based patient decision aid plus a paper workbook.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: General sleep education
Description: Web-based information about sleep plus a paper workbook
Study: NCT01382147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C, Mitoxantrone, Daunorubicin, Thioguanin
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C, Mitoxantrone, Daunorubicin, Thioguanin
Description: Chemotherapy
Study: NCT03865797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.The intervention will be done before the training session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control active
Description: Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The objective of the application of these exercises is to increase the control of the Core, and therefore improve the stability both central and of members. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises (13) will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.
Study: NCT04233918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: Part A: Single IV dose Part B \& C: IV dose Q4W